+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Chronic Kidney Disease: Global Markets and Technologies Through 2023

  • ID: 4768771
  • Report
  • Region: Global
  • 153 Pages
  • BCC Research
UP TO OFF
until Nov 23rd 2019
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Ardelyx
  • Bristol-Myers Squibb
  • Glaxosmithkline
  • Medicines Co.
  • Noxxon Pharma A/G
  • MORE

Report Scope:

Five-year projections for market activity and value are provided. Treatment types and trends for acute and chronic kidney failure, pricing considerations for medications, dialysis products (dialysis machines, dialysates and dialyzers), therapies, surgical procedures, companies, industry structure and participating companies are included in the study.

Qualitative information on disease overview, epidemiology and clinical burden of CKD is covered in detail. Further, detailed description about diagnostic methods such as blood tests, medical imaging; treatment, disease management strategies like pharmacological interventions, medical device interventions such as dialysis and kidney transplantation procedures and dietary supplements are covered. Further supporting technologies such as smartphone apps, tools and emerging technologies in dialysis and kidney transplantation procedures are also covered. Special emphasis is given to new, emerging technologies for the treatment of CKD. Market specific information on global dynamics (drivers, challenges and emerging opportunities) are covered. CKD disease management involves tedious labor, safety and cost analyses, knowledge of current policies, regulations and reimbursement. Further clinical trial and the patent landscape is also covered in the report. Profiles and the overall competitive landscape of companies/manufacturers engaged in offering drugs and medical equipment for treating CKD are covered in the report.

Quantitative market size and forecast information is covered broadly by treatment, user settings and region. By treatment, the market is categorized into drugs (treatment of complications associated due to CKD, drugs for dialyzed patient groups, post-kidney transplantation procedures are covered) and medical equipment (dialysis-hemodialysis, peritoneal dialysis, kidney transplantation procedure surgical equipment). By user settings, the CKD market is categorized into hospitals, specialty clinics and homecare. By region, the market is categorized into North America, Europe, Asia-Pacific and RoW (Latin America, Middle East and Africa).

The Report Includes:

  • 37 data tables and 22 additional tables
  • A detailed overview of the global markets for Chronic Kidney Disease (CKD)
  • Analyses of global market trends with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Information on the current state of chronic kidney disease, with an emphasis on biomarkers, diagnostic methods, and mobile apps that support effective disease state management
  • Key insight into research on CKD comorbidities such as Diabetes and Metabolic Disease, as well as treatment methods and diagnostics
  • A look at the impact of regulatory, environmental, and legislative issues on the global CKD market
  • Profiles of major market players within the industry, including Abbott Laboratories, Eli Lilly and Co., Eisai, Inc., Merck & Co. and Sanofi-Aventis
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Ardelyx
  • Bristol-Myers Squibb
  • Glaxosmithkline
  • Medicines Co.
  • Noxxon Pharma A/G
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

  • Key Findings

Chapter 3 Background of Chronic Kidney Disease

  • Kidney Function
  • Renal Disease
  • Symptoms
  • Hospitalization for Kidney Disease
  • Costs of Chronic Kidney Disease
  • Epidemiology of Renal Disease
  • Cause of Chronic Kidney Disease
  • Pathology of Chronic Kidney Disease
  • Anemia
  • Diabetic Nephropathy
  • Electrolyte Abnormality
  • Diagnostic Methods for Identification and Detection of Chronic Kidney Disease
  • Clinical Markers for the Detection of Chronic Kidney Disease
  • Treatment and Management of Chronic Kidney Disease (CKD)
  • Pharmaceutical Therapies
  • Antihyperkalemia
  • Antihyperphosphatemia
  • Cholesterol Management Medications
  • Diuretics
  • Erythropoiesis-Stimulating Agents
  • Iron Therapy
  • Glucose Management
  • Other
  • Medical Device Interventions
  • Dialysis
  • Kidney Transplant
  • Renal Dialysis
  • Principles of Renal Dialysis
  • Function of Renal Dialysis
  • Types of Renal Dialysis
  • Hemodialysis
  • Peritoneal Dialysis
  • Additional Medications for Dialysis Patients
  • Medications for CKD Patients on Peritoneal Dialysis
  • Novel Kidney Treatment in Development
  • Portable, Cartridge-Based Hemodialysis Device
  • Wearable Peritoneal Dialysis Device
  • Kidney Transplantation
  • The Transplant Procedure
  • Waiting List for Kidney Transplantation
  • Economics of Kidney Transplant
  • Drugs Used in Conjunction with Kidney Transplantation
  • Immunosuppressant Agents for Kidney Transplant
  • Software and Mobile Applications for Chronic Kidney Disease Management
  • Smartphone Technology and Mobile Apps
  • Mobile Apps for CKD Patients
  • Mobile Apps for CKD Professionals
  • Diet and Nutrition Apps
  • Medication Apps
  • Renal LabApps

Chapter 4 Market Overview

  • Overview
  • Factors Affecting Renal Dialysis Market
  • Drivers of the Renal Dialysis Market
  • Current Challenges for the Renal Dialysis Market
  • Regulations and Reimbursement Landscape
  • U.S. FDA 510(k) Approval
  • Reimbursement Landscape

Chapter 5 Market Segment Analysis

  • Segment Analysis, by Treatment Intervention
  • Pharmaceutical Drugs
  • Medical Device Interventions-Dialysis
  • Analysis of Medical Device Intervention, by Product
  • Analysis of Medical Device Intervention/Dialysis Market, by End User

Chapter 6 Market Breakdown by Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Asia-Pacific
  • China
  • India
  • Japan
  • RoW
  • Latin America
  • Africa
  • Middle East

Chapter 7 Patent Review/ New Developments

  • Patents, by Year
  • Patents, by Type
  • Patents, by Company
  • Patents, by Country
  • Patents, by Assignee
  • New Developments
  • Prevention and Treatment of Chronic Kidney Disease
  • Use of Dynamin Ring Stabilizers
  • Compositions for the Treatment of Kidney Disease
  • Methods and Compositions in AKI
  • Treatment of CKD and Other Renal Dysfunction: GDF15 Modulator
  • Methods for Diagnosing and Assessing Kidney Disease
  • Treatment and Prevention of Chronic Kidney Disease
  • Pharmaceutical Composition for Treating Chronic Kidney Disease
  • Detection of Chronic Kidney Disease and Disease Progression
  • Methods and Composition for Diagnosis and Prognosis of Renal Injury and Renal Failure
  • Treatment for Chronic Kidney Disease
  • PromarkerD-A Predictive and Diagnostic Test for Chronic Kidney Disease

Chapter 8 Competitive Landscape

  • Overview
  • Pharmaceutical Manufacturers
  • Dialysis Equipment and Accessories Manufacturers
  • Market Share Analysis for Dialysis
  • Recent Industry Developments
  • Key Mergers and Acquisitions

Chapter 9 Company Profiles

  • Abbott Laboratories
  • Abbvie Biotherapeutics Corp.
  • Acceleron Pharma, Inc.
  • Acon Laboratories, Inc.
  • Akebia Therapeutics, Inc.
  • AM-Pharma
  • Amag Pharmaceuticals
  • American Regent, Inc.
  • American Renal Associates
  • Amgen
  • Ardelyx
  • Arkray, Inc.
  • Asahi Kasei Kuraray Medical Co.
  • Astellas Pharma U.S., Inc.
  • Astrazeneca Plc
  • Aurinia Pharmaceuticals, Inc.
  • Astute Medical, Inc.
  • Aveo Pharmaceuticals, Inc.
  • Awak Technologies, Inc.
  • B. Braun Medical, Inc.
  • Bard Access Systems, Inc.
  • Baxter International, Inc.
  • Bayer Healthcare Pharmaceuticals Llc
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cantel Medical
  • Centers For Dialysis Care
  • Chemocentryx, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Concert Pharmaceuticals, Inc.
  • Davita, Inc.
  • Dialysis Clinic, Inc. (Dci)
  • Diamedica Therapeutics, Inc.
  • Diversified Specialty Institutes (Dsi)
  • Eli Lilly And Co.
  • Eisai, Inc.
  • Fibrogen, Inc.
  • Fresenius Medical Care (Fmc)
  • Genentech, Inc.
  • Glaxosmithkline
  • Hospira, Inc.
  • Incyte Corp.
  • Janssen Pharmaceuticals, Inc.
  • Keryx Biopharmaceuticals
  • Kidney Center, Inc.
  • Kringle Pharma, Inc.
  • Liberty Dialysis
  • Medcomp
  • Medgenics, Inc.
  • Medicines Co.
  • Merck & Co.
  • Mylan, Inc.
  • Navilyst Medical
  • Nephrogenex, Inc.
  • Nipro Corp.
  • Northwest Kidney Centers
  • Novartis Pharmaceuticals
  • Novo Nordisk A/S
  • Noxxon Pharma A/G
  • Nxstage Medical, Inc.
  • Outset Medical, Inc.
  • Pfizer Pharmaceutical
  • Prometheus Laboratories, Inc.
  • Renal Research Institute (Rri) Llc
  • Quanta Fluid Solution Ltd.
  • Sanofi-Aventis
  • Satellite Healthcare/Wellbound Concert
  • Shire Pharmaceuticals Group
  • Thrasos Innovation
  • Tricida, Inc.
  • U.S. Renal Care Inc. (Usrc)
  • Vascular Access Centers
  • Vascular Pharmaceuticals, Inc.
  • Vifor Pharma Ltd.

List of Tables
Summary Table: Global Market for Chronic Kidney Disease, by Type, Through 2023
Table 1: Stages of Chronic Kidney Disease: A Clinical Action Plan
Table 2: Awareness, Treatment and Measures of Control of Risk Factors, 1998-2012
Table 3: Incidence of ESRD, by Country, 2015
Table 4: Prevalence of ESRD, by Country, 2015
Table 5: Incidence of ESRD Patients (Due to Diabetes), by Country, 2015
Table 6: Kidney Transplant Rates, by Country, 2015
Table 7: Pathologies and Etiologies Associated with CKD
Table 8: Common Medications Associated with Chronic Kidney Disease
Table 9: Prevalence of Hypertension and Dyslipidemia, by CKD Stage
Table 10: Patients Share of Commonly Prescribed Medication for Chronic Kidney Disease
Table 11: Recommended Antihypertensive Agents for Patients with Chronic Kidney Disease and Hypertension
Table 12: Commonly Prescribed Ace Inhibitors
Table 13: Commonly Prescribed Angiotensin Receptor Blockers
Table 14: Commonly Prescribed Beta Blockers
Table 15: Commonly Prescribed Calcium Channel Blockers
Table 16: Commonly Prescribed Phosphate Binders
Table 17: Commonly Prescribed Statins
Table 18: Commonly Prescribed Bile Acid Sequestrants
Table 19: Commonly Prescribed Fibrates
Table 20: Commonly Prescribed Diuretics
Table 21: Commonly Prescribed Erythropoiesis-Stimulating Agents
Table 22: Commonly Prescribed Iron Supplements
Table 23: Commonly Prescribed Glucose Management Drugs
Table 24: Commonly Prescribed Medication for Chronic Kidney Disease
Table 25: Commonly Prescribed Immunosuppressant Drugs
Table 26: Immunosuppression Maintenance Regimens
Table 27: Immunosuppression Induction Drug Therapies
Table 28: Global Market for Chronic Kidney Disease, by Type, Through 2023
Table 29: Reimbursement of Dialysis Services per Week, 2011-2013
Table 30: Global Market for CKD Pharmaceutical Drugs, by Type, Through 2023
Table 31: Global Market for CKD Stage 1-5 Drugs, by Region, Through 2023
Table 32: Common Drug Classes Used, by Part D-Enrolled Dialysis Patients, 2013
Table 33: Global Market for Dialysis Drugs, by Region, Through 2023
Table 34: Global Market for Post-Transplantation Drugs, by Region, Through 2023
Table 35: Global Market for Dialysis Devices, by Type, Through 2023
Table 36: Global Market for Hemodialysis, by Region, Through 2023
Table 37: Key Peritoneal Products and Manufacturers
Table 38: Global Market for Peritoneal Dialysis, by Region, Through 2023
Table 39: Global Market for Dialysis Devices, by Product, Through 2023
Table 40: Global Market for Dialysis Accessories, by Region, Through 2023
Table 41: Global Market for Dialysis Equipment, by Region, Through 2023
Table 42: Global Market for Dialysate and Other Solutions, by Region, Through 2023
Table 43: Global Market for Dialysis Devices, by End User, Through 2023
Table 44: Global Market for Medical Care Centers, by Region, Through 2023
Table 45: Global Market for In-Home Dialysis, by Region, Through 2023
Table 46: Global Market for Chronic Kidney Disease, by Region, Through 2023
Table 47: North American Market for Chronic Kidney Disease, by Country, Through 2023
Table 48: European Market for Chronic Kidney Disease, by Country, Through 2023
Table 49: Asia-Pacific Market for Chronic Kidney Disease, by Country, Through 2023
Table 50: Rest of the World Market for Chronic Kidney Disease, by Country, Through 2023
Table 51: Patents on Renal Dialysis Equipment and Technology, by Year, 2014-2017
Table 52: Patents on Renal Dialysis Equipment and Technology, by Type, 2014-2017
Table 53: Patents on Renal Dialysis Equipment and Technology, by Company, 2014-2017
Table 54: Patents on Renal Dialysis Equipment and Technology, by Country, 2014-2017
Table 55: Patent Shares of Renal Dialysis Equipment and Technology, 2014-2017
Table 56: Patents on Renal Dialysis Equipment and Technology, by Assignee, 2014-2017
Table 57: New Developments in Renal Dialysis, 2014-2017
Table 58: Key Mergers and Acquisitions in Renal Dialysis, 2014-2017

List of Figures
Summary Figure: Global Market for Chronic Kidney Disease, by Type, 2017-2023
Figure 1: Patents on Renal Dialysis Equipment and Technology, by Year, 2014-2017
Figure 2: Patents on Renal Dialysis Equipment and Technology, by Type, 2014-2017
Figure 3: Patents on Renal Dialysis Equipment and Technology, by Assignee, 2014-2017
Figure 4: Global Market Share of Dialysis Medical Devices, by Company, 2017

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Ardelyx
  • Bristol-Myers Squibb
  • Glaxosmithkline
  • Medicines Co.
  • Noxxon Pharma A/G
  • MORE

The healthcare sector underwent a remarkable change in the last decade due to the increased use of innovative products and therapies. The evolution of dialysis technology contributes to the development of the healthcare sector. Researchers focus on innovative products and machines for dialysis. Companies producing dialysis products are investing more in R&D. Home dialysis and portable dialysis machines are gaining popularity among patients suffering from end-stage kidney disease, kidney failure and acute kidney injury.

The focus of this report is the role of drugs and medical device intervention (dialysis) in the treatment and management of Chronic Kidney Disease (CKD).

Reasons for Doing This Study

The economic impact of CKD remains a global crisis. Even with the gradual shift in treatment guidelines and innovation, nearly 10% of the U.S. population suffers from this disease that is often referred to as a silent killer. Today, one out of seven people in the U.S. have CKD. Most are unaware that they have it. Millions of patients go undiagnosed each year due to lack of treatment and affordable care. Annual treatment costs for Medicare beneficiaries with CKD are as high as $64 billion, with an additional $34 billion spent on treating patients with end-stage renal disease (ESRD).

Expenditures related to kidney failure consume about 10% of the total Medicare budget, accounting for the treatment of less than 1% of all Medicare recipients. The imbalance between cost and clinical outcomes associated with CKD create an impenetrable health care burden.

Kidney failure is the ninth-leading cause of death in the U.S., accounting for about 47,000 fatalities in 2013. Approximately 33 million Americans currently have CKD. Another 20 million are at increased risk of developing CKD.

More than two million people, worldwide, receive treatment: dialysis or a kidney transplant. Of the subset being treated for kidney failure, the majority are treated in only five countries: the U.S., Japan, Germany, Brazil and Italy. These five countries represent only 12% of the world population. Forecasts suggest that the number of cases of kidney failure will increase disproportionately in developing countries, like China and India, where the number of elderly people is increasing.

CKD is a global health problem. This report provides a regional analysis of costs and clinical outcomes related to the management of CKD around the world. Data is further segmented by CKD stage, end user and application.

This market analysis is intended to provide analytical information to optimize business strategies. The ability to execute operating plans effectively rests on a company’s ability to integrate industry research and data.

Note: Product cover images may vary from those shown
5 of 5
  • Abbott Laboratories
  • Abbvie Biotherapeutics Corp.
  • Acceleron Pharma, Inc.
  • Acon Laboratories, Inc.
  • Akebia Therapeutics, Inc.
  • AM-Pharma
  • Amag Pharmaceuticals
  • American Regent, Inc.
  • American Renal Associates
  • Amgen
  • Ardelyx
  • Arkray, Inc.
  • Asahi Kasei Kuraray Medical Co.
  • Astellas Pharma U.S., Inc.
  • Astrazeneca Plc
  • Astute Medical, Inc.
  • Aurinia Pharmaceuticals, Inc.
  • Aveo Pharmaceuticals, Inc.
  • Awak Technologies, Inc.
  • B. Braun Medical, Inc.
  • Bard Access Systems, Inc.
  • Baxter International, Inc.
  • Bayer Healthcare Pharmaceuticals Llc
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cantel Medical
  • Centers For Dialysis Care
  • Chemocentryx, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Concert Pharmaceuticals, Inc.
  • Davita, Inc.
  • Dialysis Clinic, Inc. (Dci)
  • Diamedica Therapeutics, Inc.
  • Diversified Specialty Institutes (Dsi)
  • Eisai, Inc.
  • Eli Lilly And Co.
  • Fibrogen, Inc.
  • Fresenius Medical Care (Fmc)
  • Genentech, Inc.
  • Glaxosmithkline
  • Hospira, Inc.
  • Incyte Corp.
  • Janssen Pharmaceuticals, Inc.
  • Keryx Biopharmaceuticals
  • Kidney Center, Inc.
  • Kringle Pharma, Inc.
  • Liberty Dialysis
  • Medcomp
  • Medgenics, Inc.
  • Medicines Co.
  • Merck & Co.
  • Mylan, Inc.
  • Navilyst Medical
  • Nephrogenex, Inc.
  • Nipro Corp.
  • Northwest Kidney Centers
  • Novartis Pharmaceuticals
  • Novo Nordisk A/S
  • Noxxon Pharma A/G
  • Nxstage Medical, Inc.
  • Outset Medical, Inc.
  • Pfizer Pharmaceutical
  • Prometheus Laboratories, Inc.
  • Quanta Fluid Solution Ltd.
  • Renal Research Institute (Rri) Llc
  • Sanofi-Aventis
  • Satellite Healthcare/Wellbound Concert
  • Shire Pharmaceuticals Group
  • Thrasos Innovation
  • Tricida, Inc.
  • U.S. Renal Care Inc. (Usrc)
  • Vascular Access Centers
  • Vascular Pharmaceuticals, Inc.
  • Vifor Pharma Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll